On the other hand, increased expressions of BRG1 and BRM were associated with development and progression of prostate cancer (Sun et al, 2007), cutaneous melanoma (Lin et al, 2010) and gastric carcinoma (Sentani et al, 2001). Here, SMARCA4 is linked to prostate cancer.